Drugs by condition
Drugs approved for paroxysmal nocturnal hemoglobinuria
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
8
Still marketed, NDA or BLA
Drug classes
4
Novel drugs
6
New molecular entities and new biologics
In development
13
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for paroxysmal nocturnal hemoglobinuria.
- Epysqli (Eculizumab-Aagh) · Samsung Bioepis CO LTD Jul 19, 2024
- Piasky (Crovalimab-Akkz) · Genentech INC NovelOrphanJun 20, 2024
- Bkemv (Eculizumab-Aeeb) · Amgen INC May 28, 2024
- Voydeya (Danicopan) · Alexion Pharms INC NovelBreakthrough therapyOrphanMar 29, 2024
- Fabhalta (Iptacopan Hydrochloride) · Novartis NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanDec 5, 2023
All approved drugs for paroxysmal nocturnal hemoglobinuria, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Drugs in development for paroxysmal nocturnal hemoglobinuria
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- HRS-5965Phase 36 trials
Chengdu Suncadia Medicine Co., Ltd. · Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria
- CemdisiranALN-CC5Phase 35 trials
Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)
- HSK39297Phase 35 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)
- MY008211APhase 35 trials
Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)
- FXS6837Phase 34 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Paroxysmal Nocturnal Hemoglobinuria, Primary IgAN, IgAN
- NTQ5082Phase 34 trials
Nanjing Chia-tai Tianqing Pharmaceutical · Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy
- VSA012Phase 31 trial
Bisirna Therapeutics (Suzhou) Co., Ltd. · Paroxysmal Nocturnal Hemoglobinuria, PNH
- NM8074Phase 28 trials
NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria
- LP-005Phase 24 trials
Longbio Pharma · Periodontitis, Paroxysmal Nocturnal Hemoglobinuria, Complement-mediated Renal Diseases
- HS-10542Phase 22 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease
- SGB-9768Phase 22 trials
Suzhou Sanegene Bio Inc. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN), C3 Glomerulopathy
- SLN12140Phase 22 trials
Linno Pharmaceuticals, Inc. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria (PNH)
- XH-S003Phase 22 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy
More on paroxysmal nocturnal hemoglobinuria: recruiting trials · published research
Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.